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ABSTRACT
Background. Since its introduction, the sentinel lymph
node biopsy (SLNB) has become the standard staging
procedure in clinical node-negative melanoma patients. A
negative SLNB, however, does not guarantee a recurrence-
free survival. Insight into metastatic patterns and risk fac-
tors for recurrence in SLNB negative melanoma patients
can provide patient tailored guidelines.
Methods. Data concerning melanoma patients who
underwent SLNB between 1996 and 2015 in a single center
were prospectively collected. Cox regression analyses were
used to determine variables associated with overall recur-
rence and distant first site of recurrence in SLNB-negative
patients.
Results. In 668 patients, SLNBs were performed between
1996 and 2015. Of these patients, 50.4 % were male and
49.6 % female with a median age of 55.2 (range 5.7–88.8)
years. Median Breslow thickness was 2.2 (range 0.3–20)
mm. The SLNB was positive in 27.8 % of patients.
Recurrence rates were 53.2 % in SLNB-positive and
17.9 % in SLNB-negative patients (p\ 0.001). For SLNB-
negative patients, the site of first recurrence was distant in
58.5 %. Melanoma located in the head and neck region
(hazard ratio 4.88, p = 0.003) and increasing Breslow
thickness (hazard ratio 1.15, p = 0.013) were predictive
for distant first site of recurrence in SLNB-negative
patients. SLNB-negative patients with a nodular melanoma
and ulceration had a recurrence rate of 43.1 %; the site of
recurrence was distant in 64 % of these patients.
Conclusions. The recurrence rates of SLNB-negative
nodular ulcerative melanoma patients approach those of
SLNB-positive patients. Stringent follow-up is recom-
mended in this subset of patients.
Cutaneous melanoma mainly spreads via the lym-
phogenic route from the sentinel lymph nodes to the
adherent lymph node basin. After decades of experience,
we now know that in negative sentinel lymph node biopsy
(SLNB), skip metastases are rare.1,2 Since its introduction
in the early 1990s by Donald Morton, SLNB has become a
widely accepted staging procedure and has become one of
the most important prognostic tools in predicting outcome
in cutaneous melanoma.3–7 At time of primary staging,
approximately 20 % of melanoma patients are SLNB
positive, with a false-negative rate less than 5 %.1,8–10
SLNB positivity is associated with several clinico-
pathologic characteristics, such as Breslow thickness,
mitosis, and the presence of ulceration.11–13 The risk for
recurrent disease is associated with this SLNB status,
resulting in higher recurrence rates of up to 47 % in SLNB-
positive patients and lower recurrence rates of 24 % in
SLNB-negative patients.14–17 Some of these SLNB-nega-
tive patients have a distant first site of recurrence and even
seem to skip the lymphogenic metastatic route.15 These
patients with direct hematogenous recurrences may either
have different clinicopathologic characteristics or more
aggressive tumor biology.
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The purpose of this study was to evaluate risk factors for
recurrent disease and distant first site of recurrence in
SLNB-negative melanoma patients.
METHODS
The study population consisted of all consecutive mel-
anoma patients who underwent a wide excision with a
1–2 cm margin according to the international melanoma
guidelines and a SLNB at the University Medical Center
Groningen (UMCG) between 1996 and 2015. The SLNB
technique used at the UMCG has been described elsewhere
in detail.18 Patient- and tumor-related clinicopathologic
characteristics were prospectively collected in a database.
Data concerning patient and tumor clinicopathologic
characteristics, follow-up, recurrence, and survival were
retrieved from the database for analysis.
Statistics were performed by IBM SPSS 22.0 (IBM
SPSS, Chicago, IL, USA). Differences between groups
were analyzes by the Chi square test for nominal variables;
for continuous variables, the one-way ANOVA or Kruskal–
Wallis test was used. Cox regression analyses were used to
determine variables associated with overall recurrence in
all patients and distant first site of recurrence in SLNB-
negative patients. Overall recurrence was defined as any
recurrence besides recurrence in the same basin as the
SLNB. On the basis of our data, the following were
included in the analysis: patient demographics, histologic
type, location of primary lesion, Breslow thickness, Clark
level, ulceration, mitosis, regression, lymphangioinvasion,
use of immunosuppressant medication, and whether the
primary excision was radical. Variables were checked for
correlation with Pearson’s or Spearman’s rho. Variables on
a 20 % significance level in the univariate Cox regression
were entered in the multivariate Cox regression analysis. In
the multivariate analysis, variables were checked for mul-
ticollinearity and confounding. Confounding limit was set
at 10 %. Confounders and variables with a multicollinear
association were excluded from multivariate analysis.
Variables with p\ 0.05 in the multivariate analysis were
identified as significant factors.
Melanoma-specific survival (MSS), disease-free sur-
vival (DFS), and time to death from moment of first
recurrence were analyzed by the Kaplan–Meier test. SLNB
was defined as falsely negative if the first site of recurrence
was in the same basin as the SLNB, and also when com-
bined with systemic recurrence. To determine whether a
SLNB was falsely negative in case of systemic recurrence,
all positron emission tomography/computed tomography
scans performed at the moment of systemic recurrence
were reviewed to check for nodal involvement in the same
basin as the SLNB. Because of the 100 % recurrence rate
in the same basin in falsely negative SLNB patients, they
were not included in the Cox regression analysis.
In the case of multisite recurrence, the recurrence site
with the worst prognosis was scored as the first site of
recurrence. For example, in the case of recurrence in the
retroperitoneal lymph nodes and brain metastases, brain
metastases were scored as the first site of recurrence. Fol-
low-up was conducted in the UMCG. We received
institutional review board approval, and the study was
conducted according to the declaration of Helsinki.
RESULTS
During the study period, a SLNB was performed in 668
patients. Baseline clinicopathologic characteristics of all
patients are displayed in Table 1. Median (range) age at
diagnosis of primary melanoma was 55.2 (5.7–88.8) years,
and superficial spreading melanoma was the most common
histologic subtype (62 %). Median overall Breslow thick-
ness was 2.2 (0.30–20.0) mm. The median Breslow
thickness in the different histologic subtypes was as fol-
lows: superficial spreading melanoma (n = 414), 1.8
(0.30–9.0) mm; nodular melanoma (n = 192), 3.4 (0.9–20)
mm; acral lentiginous melanoma (n = 21), 3.6 (1.1–11)
mm; other melanomas (n = 28), 3.3 (0.85–17.00) mm; and
unknown histologic subtype (n = 13), 3.00 (1.0–7.0) mm.
SLNB was positive in 27.8 % of patients. In SLNB-nega-
tive patients, 24 patients experienced a nodal recurrence in
the same basin as the SLNB, resulting in a SLNB false-
negative rate of 3.6 %. In Table 1, the differences between
the baseline clinicopathologic characteristics are displayed
by SLNB status. During the median follow-up of 58.8
(range 1.8–190) months, a recurrence was diagnosed in 82
of the truly SLNB-negative patients (17.9 %) and in 99
SLNB-positive patients (53.2 %).
Multivariate Cox regression analysis revealed the fol-
lowing variables to be associated with overall recurrence in
SLNB-negative patients: male sex (hazard ratio [HR] 1.78,
p = 0.025), increasing age (HR 1.02, p = 0.0085) per year,
melanoma located in the head and neck region (HR 2.16,
p = 0.024), nodular melanoma (HR 1.82, p = 0.028), and
presence of ulceration (HR 2.11, p = 0.002). In SLNB-
positive patients, excisional biopsy decreased the risk for
recurrence (HR 0.49, p = 0.005) as well as melanoma
located on the upper extremity (HR 0.37, p = 0.045). Male
sex (HR 1.10, p = 0.048), increasing Breslow thickness (HR
1.09, p = 0.048), and the presence of ulceration (HR 2.15,
p\ 0.001) were associated with recurrence in this group.
Mitosis and Clark level were not included in both multi-
variate analyses because of multicollinearity with Breslow
thickness (Table 2). In SLNB-negative patients with a
nodular melanoma, the recurrence rate was 38 (29.7 %) of
Risk Factors for Recurrence After Negative SLNB 143
128; if ulceration was also present in the primary melanoma,
the recurrence rate was increased to 43.1 %. The site of
recurrence was distant in 64 % of these patients. Of all
SLNB-negative patients, 12.7 % had nodular ulcerated
melanoma. In the entire group of SLNB-negative patients
with nodular melanoma, 25 % eventually progressed to
distant disease, 34.5 % if ulceration was also present.
Table 3 shows the distribution of recurrence patterns for
both SLNB-negative and -positive patients. The most
common site of first recurrence was distant in all SLNB
categories. In SLNB-negative patients, this was 58.5 % of
all first recurrence sites. Of all 181 patients with recur-
rence, 77 % developed overall distant disease at some point
in the course of their disease. If patients progressed to stage
IV disease during the course of their disease, the largest
portion of these distant recurrences was American Joint
Committee on Cancer stage M1c (82.5 %).
MSS and DFS was significantly worse for SLNB-posi-
tive patients compared to SLNB-negative patients
(p\ 0.001). If a recurrence had occurred, survival did not
differ between SLNB-negative and SLNB-positive
patients. There was a significant difference between MSS
TABLE 1 Clinicopathologic characteristics overall, in SLNB-negative patients, and in SLNB-positive patients (n = 668)
Characteristic Overall (n = 668) SLNB negative (n = 458) SLNB positive (n = 186) p
Sex 0.070
Male 337 (50.4) 220 104
Female 331 (49.6) 238 82
Age, yearsa 55.2 (5.7–88.8) 55.3 (11.5–88.8) 53.5 (5.7–88.8) 0.890
Site of primary lesion 0.003
Lower extremity 228 (34.1) 149 68
Head and neck 95 (14.2) 75 16
Trunk 256 (38.3) 166 86
Upper extremity 89 (13.3) 68 16
Histologic typing 0.705
Superficial spreading 414 (62) 291 110
Nodular 192 (28.7) 128 56
Acral lentiginous 21 (3.1) 12 7
Otherb 28 (4.2) 20 8
Breslow thickness, mm 2.2 (0.30–20.0) 1.9 (0.3–20.0) 3.00 (0.8–13.0) \0.001
T stage \0.001
T1 (\1.00 mm) 38 (5.7) 7 0
T2 (1.01–2.00 mm) 271 (40.6) 155 34
T3 (2.01–4.00 mm) 244 (36.5) 114 83
T4 ([4.00 mm) 114 (17.1) 52 37
Clark level 0.035
II 7 (1.0) 5 2
III 137 (20.5) 109 26
IV 472 (70.7) 312 141
V 40 (6.0) 23 14
Ulceration 0.001
Yes 223 (33.4) 133 80
No 435 (65.1) 319 103
Mitosis 0.055
Yes 561 (84) 380 159
No 45 (6.7) 37 7
Data are presented as n (%) or median (range)
SLNB sentinel lymph node biopsy
a Age at diagnosis of primary melanoma
b Other histologic types are verrucous, spitzoid, epithelioid, desmoplastic melanoma, and lentigo maligna melanoma
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TABLE 2 Univariate and multivariate Cox regression analysis of clinicopathologic characteristics associated with overall recurrence in all








positive (n = 99)
Multivariate SLNB
positive
HR p HR p 95 % CI HR p HR p 95 % CI
Sex
Male 126 (61.5) 2.34 \0.001* 1.78 0.025 1.08–2.94 1.34 0.156* 1.10 0.048* 1.01–1.20
Female 79 (38.5)
Agea 58.66 (19.2–81.4) 1.03 0.001* 1.02 0.008* 1.01–1.04 1.02 0.036* 1.01 0.127 0.99–1.03
Site of primary lesion
Lower extremity 71 (34.6) 1.00 0.010* 1.00 0.006* 1.00 0.100 1.00 0.035*
Head/neck 34 (16.6) 2.20 0.011* 2.16 0.024* 1.11–4.21 1.48 0.264 1.79 0.144 0.82–3.92
Trunk 84 (41) 1.47 0.156 1.34 0.346 0.73–2.64 0.93 0.600 0.89 0.687 0.53–1.52
Upper extremity 16 (7.8) 0.56 0.206 0.43 0.068 0.17–1.07 0.39 0.046* 0.37 0.045* 0.14–0.98
Histologic typing
Superficial spreading 106 (51.7) 1.00 0.002* 1.00 0.164 1.00 0.840
Nodular 74 (36.1) 2.50 \0.001* 1.82 0.028* 1.07–3.09 0.91 0.669
Acral lentiginous 11 (5.4) 3.45 0.019 2.76 0.080 0.89–8.59 1.46 0.418
Otherb 10 (4.9) 1.82 0.257 1.02 0.978 0.30–3.50 1.31 0.534
Excision radical
Yes 153 (74.6) 0.93 0.786 0.49 0.001* 0.49 0.005* 0.30–0.81
No 52 (25.4)
Breslow thickness, mm 3.00 (1.05–20.00) 1.16 \0.001* 1.06 0.151 0.98–1.16 1.11 0.007* 1.09 0.048* 1.00–1.20
Clark level
II 1 (0.5) 1.91 0.524
III 27 (13.2) 0.79 0.443 0.60 0.133
IV 150 (73.2) 1.00 0.042* 1.00 0.311
V 23 (11.2) 2.39 0.012* 1.39 0.333
Ulceration
Yes 110 (53.7) 3.02 \0.001* 2.11 0.002* 1.31–3.39 2.28 \0.001* 2.15 \0.001* 1.40–3.29
No 92 (44.9)
Mitosis
Yes 178 (86.8) 5.58 0.088 2.32 0.240
No 4 (2.0)
Regression
Yes 22 (10.7) 0.99 0.840 0.97 0.206
No 111 (54.1)
Lymphangioinvasion
Yes 18 (8.8) 1.14 0.081 1.16 0.172 0.94–1.43 0.92 0.641
No 184 (89.8)
Immunosuppressant medication
Yes 7 (3.4) 2.37 0.143 1.12 0.819 1.97 0.193 0.71–5.43
No 198 (96.6)
Data are presented as n (%) or median (range)
SLNB sentinel lymph node biopsy, NA not applicable
* p\ 0.05. All variables with significance level of p\ 0.2 in univariate Cox regression analysis were entered into multivariate Cox regression
analysis
a Age at diagnosis of primary melanoma
b Other histologic types are verrucous, spitzoid, epithelioid, desmoplastic melanoma, and lentigo maligna melanoma
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and DFS in SLNB-negative patients with ulcerated and
nodular melanoma compared to the overall SLNB-negative
group (p\ 0.001; Fig. 1).
Multivariate Cox regression analysis revealed melano-
mas located on the head and neck (HR 4.88, p = 0.003),
trunk (HR 3.33, p = 0.012), and upper extremity (HR 6.60,
p = 0.008) to be associated with distant first site of
recurrence in SLNB-negative melanoma patients as well as
increasing Breslow thickness (HR 1.15, p = 0.013). The
absence of mitosis (HR 0.06, p = 0.035) is protective for
distant first site of recurrence in SLNB-negative patients
(Table 4).
DISCUSSION
The current study revealed that in SLNB-negative
patients, recurrence rates approach the recurrence rates of
SLNB-positive patients (43.1 vs. 53.2 %) if the unfavor-
able variables nodular histologic subtype and ulceration are
accounted for. These pathologic characteristics are present
in 12.7 % of SLNB-negative melanoma patients. As dis-
played by the Kaplan–Meier curves in Fig. 1, DFS and
MSS is significantly worse for SLNB-negative nodular and
ulcerated melanoma patients compared to the overall
SLNB-negative group.
TABLE 3 Recurrence rates and site of first recurrence in SLNB-negative and -positive patients
Characteristic Overall, n (%) SLNB negative, n SLNB positive, n p
Recurrence \0.001
Yes 205 (30.7) 82 99
No 463 (69.3) 376 87
Type of first recurrence 0.053
Locoregional 30 (14.7) 14 16
In transit 43 (21.1) 18 25
Basin of SLNB/CLND 30 (14.7) 0 9
Lymphatic 3 (1.5) 1 2
Distant 98 (48) 49 46
M-stage distant recurrence 0.278
M1a 4 (4.1) 3 1
M1b 12 (12.4) 4 8
M1c 80 (82.5) 42 37
Unknown 1



































FIG. 1 Survival split by sentinel lymph node biopsy negativity or positivity with nodular subtype and ulceration. a Melanoma-specific survival.
b Disease-free survival
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TABLE 4 Univariate and multivariate Cox regression analysis of clinicopathologic characteristics associated with distant first site of recurrence
in SLNB-negative patients
Characteristic Distant first recurrence (n = 48) Univariate Multivariate
HR p HR p 95 % CI
Sex
Male 32 (66.7) 1.43 0.243
Female 16 (33.3)
Age, ya 60.2 (19.4–79.6) 1.03 0.009* 1.02 0.160 0.99–1.04
Site of primary lesion
Lower extremity 11 (22.9 %) 1.00 0.113 1.00 0.011*
Head/neck 13 (27.1) 2.79 0.015* 4.88 0.003* 1.74–13.73
Trunk 20 (41.7) 1.68 0.169 3.33 0.012* 1.31–8.48
Upper extremity 4 (8.3) 1.68 0.374 6.60 0.008* 1.63–26.74
Histologic typing
Superficial spreading 19 (39.6) 1.00 0.124 1.00 0.103
Nodular 24 (50) 2.06 0.022* 1.91 0.079 0.93–3.93
Acral lentiginous 2 (4.2) 2.32 0.266 2.05 0.437 0.34–12.54
Otherb 3 (6.3) 1.18 0.795 0.13 0.107 0.01–1.56
Breslow thickness, mm 3.00 (1.05–20.0) 1.12 0.008* 1.15 0.013* 1.03–1.29
Clark level
II 0
III 9 (18.8) 1.59 0.650
IV 29 (60.4) 1.00 0.581
V 7 (14.6) 0.77 0.548
Missing 3 (6.2)
Ulceration





No 1 (2.1) 0.03 0.004* 0.06 0.035* 0.01–0.82
Missing 5 (10.4)
Regression








No 47 (97.9) 0.82 0.843
Data are presented as n (%) or median (range)
SLNB sentinel lymph node biopsy
* p\ 0.05. All variables with significance level of p\ 0.2 in univariate Cox regression analysis were entered into multivariate Cox regression
analysis
a Age at diagnosis of primary melanoma
b Other histologic types are verrucous, spitzoid, epithelioid, desmoplastic melanoma, and lentigo maligna melanoma
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Risk factors for recurrent disease in SLNB-negative
patients were increasing age, male sex, melanoma located
on the head and neck region, nodular melanoma, and
presence of ulceration (Table 2). Except for nodular mel-
anoma, the significance of these variables in predicting
recurrent disease in SLNB-negative melanoma patients
was previously illustrated by several authors.17,19,20
O’Connell et al. recently stated that nodular histologic
subtype approached significance in predicting recurrence in
SLNB negative melanoma patients.17 Obviously a negative
SLNB might create the impression of a less aggressive
melanoma; however, one cannot be so sure when it con-
cerns a nodular subtype. Because the recurrence percentage
of SLNB-negative patients with ulcerated nodular mela-
noma approaches the recurrence percentage of SLNB-
positive melanoma patients, primary tumor characteristics
are apparently more relevant for recurrence in these
patients than the status of the sentinel node. In absence of a
lymphogenous recurrence and/or positive SLNB, risk fac-
tors for distant first site of recurrence were melanoma
located on the head and neck, increasing Breslow thick-
ness, and the presence of ulceration. In SLNB-negative
patients, distant first site of recurrence occurred in 58.8 %
of all recurrences. In this subset of patients, the melanoma
seems to skip the lymphogenic metastatic route and
metastasizes directly hematogenously. Overall, it is
expected that unfavorable tumor clinicopathologic char-
acteristics should be more frequent in the SLNB-positive
group.6,12,13,21 Previous publications on SLNB-negative
patients revealed increasing Breslow thickness, ulceration,
head and neck melanoma, and unexpected lymph drainage
patterns to be predictors for distant recurrence.14–16,19,20
Unexpected or aberrant lymph drainage patterns are
expected in head and neck melanomas more than mela-
nomas located on the upper and lower extremity. An
affinity for hematogenous spread is suggested in this subset
of melanomas.22,23 This might be an explanation for our
findings.
The recurrence percentages were increased by more than
twofold in the group of SLNB-negative patients with a
nodular ulcerated melanoma compared to the whole group,
suggesting a higher likeliness of hematogenous spread in
these patients. Morton et al. posed two dissemination the-
ories: the incubator hypothesis and the marker hypothesis.
According to the first hypothesis, melanoma metastasizes
mostly to the lymph nodes and in approximately 10 %
directly via the hematogenous route. Tumor cells may grow
in the SLNB but might incubate before spreading to distant
sites. Removal of the SLNB and adherent lymph nodes can
prevent further spread. The marker hypothesis, however,
implicates a simultaneous spread. Tumor load in the SLNB
is merely a marker for the ability of the tumor to spread.
According to both hypotheses, the absence of melanoma
cells in the SLNB indicates a primary melanoma unlikely
to disseminate to distant sites.24 Perhaps the 10 % direct
distant spread posed in the incubator hypothesis is caused
by melanomas with unfavorable prognostics such as
nodular subtype and ulceration. This hematogenous dis-
semination route was also described by Gershenwald et al.,
who suggested a subset of patients with a pure hematoge-
nous dissemination route, without nodal involvement.16
Nodular melanoma is usually detected at a higher Breslow
thickness than superficial spreading melanoma, even
though the duration of change in a lesion before treatment
is shorter in nodular melanoma than the superficial
spreading type, which is suggestive for aggressive biologic
behavior.25 Lin et al. published results where a significantly
lower amount of tumor-infiltrating lymphocytes were
found in nodular melanoma compared to superficial
spreading melanoma, suggesting a different immuno-
genicity between the different histologic subtypes.26
Unfortunately, we do not routinely look for tumor-infil-
trating lymphocytes in our institution, so we were not able
to cross-reference this to our data.
The presented data on increased recurrence rates in
patients with ulcerated nodular melanoma, increasing
Breslow thickness melanoma, and head and neck local-
ization are crucial for clinicians involved in melanoma
care, as these findings can not only alter decisions on the
duration and frequency of follow-up but also increase the
awareness of the likelihood of distant recurrence in these
patients. Therefore, we propose to distinguish a high risk
for recurrence in the SLNB-negative subgroup.
SLNB-positive patients have a worse DFS compared to
SLNB-negative patients. However, when a recurrence
occurs, survival is similar. Survival was shorter in patients
with a distant first site of recurrence compared to other
recurrent sites, which has been extensively described in the
literature.15,27
Patients with unfavorable primary clinicopathologic
characteristics such as positive SLNB are already consid-
ered for adjuvant targeted therapy or immunotherapy trials.
It might also be worth considering high-risk SLNB-nega-
tive patients for inclusion. First, however, adjuvant studies
have yet to show a beneficial effect in SLNB-positive
patients with respect to MSS. Before expanding inclusion
criteria, the risk–benefit ratio should be properly assessed.
Although many researchers have focused on recurrence
patterns of melanoma, we are still unable to accurately
predict the course of the disease in many patients. We
believe that most of the biological behavior in the end can
be explained by possible unrevealed genetic mutations with
distinctive biological behavior. Today, melanoma is char-
acterized and staged by clinicopathologic features. There
might be a role for genetic profiling aiming to identify
melanoma patients with a misleadingly favorable SLNB
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pathologic prognosis whose disease is likely to recur in the
future.
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